Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia

Blood

Volumn 117, Issue 19, 2011, Pages 5261-5263

  Bachanova, Veronika ^a   Sandhu, Karamjeet ^b   Yohe, Sophia ^a   Cao, Qing ^a   Burke, Michael J ^a   Verneris, Michael R ^a   Weisdorf, Daniel ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CHILD; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INFANT; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

EID: 79955976375     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-329573     Document Type: Article

References (16)

1. Weisdorf D, Forman S. Allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia. Cancer Treat Res. 2009;144:1-14.
2. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/ maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008; 111(4):1827-1833.
3. Brenner H, Kaatsch P, Burkhardt-Hammer T, Harms DO, Schrappe M, Michaelis J. Long-term survival of children with leukemia achieved by the end of the second millennium. Cancer. 2001; 92(7):1977-1983. (Pubitemid 32952519)
4. Hahn T,Wall D, Camitta B, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant. 2005;11(11):823-861. (Pubitemid 41645639)
5. Claviez A, Eckert C, Seeger K, et al. Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia. Haematologica. 2006; 91(2):272-273.
6. Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880-3889.
7. Thomas DA, O'Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009;113(25): 6330-6337.
8. Maury S, Huguet F, Leguay T, et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica. 2010;95(2):324-328.
9. Borowitz MJ, Shuster J, Carroll AJ, et al. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 1997;89(11):3960-3966. (Pubitemid 27220939)
10. Dworzak MN, Gaipa G, Schumich A, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a druginduced regulatory phenomenon: results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group. Cytometry B Clin Cytom. 2010;78(3):147-153.
11. Tomblyn MB, Arora M, Baker KS, et al. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol. 2009; 27(22):3634-3641.
12. Verneris MR, Brunstein CG, Barker J, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft versus leukemia effect in recipients of two units. Blood. 2009;114(9):4293-4299.
13. Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009;113(13):2902-2905.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
15. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med. 1997;16(8):901-910. (Pubitemid 27198953)
16. Ratanatharathorn V, Pavletic S, Uberti JP. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects. Cancer Treat Rev. 2009;35(8):653-661.